IGC Pharma, Inc. (IGC) Earnings Signals & AI Vibe Check

Latest Filing: 10-Q  |  Filed May 15, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for IGC Pharma, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-Q, IGC Pharma, Inc.'s filing signal continuing negative.
earningsVibe SuperAnalyst™ Verdict: CONTINUING NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Continuing Negative
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does IGC Pharma, Inc. actually do?
Answer:
IGC Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease (AD) and related neurodegenerative conditions. Its lead drug candidate, IGC-AD1, is in Phase 2 clinical trials for agitation in Alzheimer's patients, showing promising interim results for reducing agitation and sleep disturbances. The company is also leveraging Artificial Intelligence (AI) and Machine Learning (ML) to develop early detection models for AD, optimize clinical trials, and explore new therapeutic applications. IGC Pharma aims to build a portfolio of differentiated therapies targeting both symptomatic relief and disease-modifying mechanisms, supported by a robust intellectual property strategy including 31 patent filings.
Question:
What are IGC Pharma, Inc.'s revenue drivers?
Answer:
Revenue is primarily generated from the Life Sciences segment, encompassing the sale of white-labeled manufactured products and formulations. The company also historically generated revenue from infrastructure projects, which ceased in fiscal year 2025.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required